Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bone Giant Cell Tumor
Conditions
Bone Giant Cell Tumor
Trial Timeline
Sep 26, 2019 → Jul 30, 2020
NCT ID
NCT03620149About Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] is a phase 2 stage product being developed by Amgen for Bone Giant Cell Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT03620149. Target conditions include Bone Giant Cell Tumor.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03620149 | Phase 2 | Terminated |
| NCT03691311 | Phase 1 | UNKNOWN |
Competing Products
20 competing products in Bone Giant Cell Tumor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Denosumab + Zoledronic Acid | Daiichi Sankyo | Phase 3 | 77 |
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus | Astellas Pharma | Phase 2 | 52 |
| Merestinib | Eli Lilly | Phase 1 | 33 |
| FORTEO + Placebo | Eli Lilly | Phase 1 | 33 |
| Arzoxifene + Placebo | Eli Lilly | Phase 3 | 77 |
| Tanezumab | Eli Lilly | Phase 3 | 77 |
| Anastrozole + Tamoxifen | AstraZeneca | Phase 3 | 77 |
| zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements | Novartis | Phase 3 | 77 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Zoledronic acid + Letrozole | Novartis | Phase 3 | 77 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Nilotinib | Novartis | Phase 1 | 33 |
| Reclast (ZOL446, zoledronic acid) | Novartis | Approved | 85 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid | Novartis | Phase 3 | 77 |
| zoledronic acid | Novartis | Phase 1 | 33 |
| Ruxolitinib continuous therapy | Novartis | Phase 2 | 52 |